Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ofatumumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis' Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.
    Novartis' Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.

    12 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326

    FDA
    12 Apr 2024
    Share Share
    Novartis' Arzerra (ofatumumab) Receives Suppl Approval in the U.S.
    Novartis' Arzerra (ofatumumab) Receives Suppl Approval in the U.S.

    12 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326

    FDA
    12 Apr 2024
    Share Share
    Novartis presents new five-year data disability outcomes and safety of Kesimpta
    Novartis presents new five-year data disability outcomes and safety of Kesimpta

    20 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/20/2650654/0/en/Novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-Kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    20 Apr 2023
    Share Share
    Novartis presents new 5-year data on disability outcomes and safety of Kesimpta
    Novartis presents new 5-year data on disability outcomes and safety of Kesimpta

    19 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis-301802531.html

    PR NEWSWIRE
    19 Apr 2023
    Share Share
    Novartis' Kesimpta Receives Approval in Europe
    Novartis' Kesimpta Receives Approval in Europe

    08 Dec 2022

    // EMA

    https://www.ema.europa.eu/en/documents/overview/kesimpta-epar-medicine-overview_en.pdf

    EMA
    08 Dec 2022
    Share Share
    Novaris's Biologic Arzerra (Ofatumumab) Receives Approval in the U.S.
    Novaris's Biologic Arzerra (Ofatumumab) Receives Approval in the U.S.

    02 Sep 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326

    FDA
    02 Sep 2022
    Share Share